Table 1 Variables associated with postoperative pneumonia (POP) in HTx recipients
From: Predictive risk factors for postoperative pneumonia after heart transplantation
Parameters | Cohort | No POP | POP | P |
|---|---|---|---|---|
N = | 175 | 116 | 59 | |
General characteristics | ||||
Recipient age (years) | 50 ± 13 | 53 [41, 60] | 54 [47, 62] | 0.140 |
Male recipients (%) | 129 (73) | 85 (73) | 44 (74) | 1.000 |
Prior diabetes mellitus (%) | 25 | 12 | 13 | 0.04 |
Prior cardiac surgery | 54 (31) | 36 (31) | 18 (31) | 1 |
Etiology of heart failure | ||||
-Dilated cardiomyopathy | 93 (42) | 68 (59) | 25 (42) | 0.06 |
-Ischemic cardiomyopathy | 53 (30) | 31 (27) | 22 (37) | 0.17 |
-Other | 29 (16) | 17 (14) | 12 (20) | 0.39 |
Standard allocation (%) | 57 (32) | 33 (28) | 24 (40) | 0.12 |
National high-priority allocation (%) | 118 (78) | 83 (72) | 35 (60) | 0.12 |
National high-priority allocation 1(%) | 97 (55) | 69 (59) | 28 (47) | 0.15 |
National high-priority allocation 2 (%) | 19 (11) | 13 (7) | 6 (11) | 1 |
National high-priority allocation 3 (%) | 2 (1) | 1 (1) | 1 (2) | 0.44 |
Pre-operative data | ||||
VA-ECMO before HTx (%) | 56 (32) | 37 (32) | 19 (32) | 1.000 |
Inotrope (%) | 87 (54) | 58 (50) | 29 (49) | 1 |
vasoconstrictor (%) | 10 (6) | 5 (4.3) | 5 (8.5) | 0.31 |
MV until the HTx (%) | 15 (9) | 4 (3.5) | 11 (19.0) | 0.002 |
VAD or TAH before HTx | 25 (14) | 18 (16) | 7 (12) | 0.65 |
Pre-operative infections (%) | 64 (37) | 43 (37.1) | 21 (35.6) | 0.98 |
Allosensitization (%) | 93 (54) | 56 (48.3) | 37 (62.7) | 0.099 |
Serum creatinine level (mg.dL−1) | 1.2 ± 0.5 | 1.14 [0.88, 1.42] | 1.16 [0.9, 1.51] | 0.469 |
Prothrombin time (%) | 57 ± 18 | 62.00 [46, 73] | 60 [46,69] | 0.632 |
Serum bilirubine level (mg/dL) | 2.9 ± 1.9 | 2.2 [1.4, 3.8] | 2.7 [1.4, 3.6] | 0.705 |
Per operative data | ||||
Cold ischemia time (min) | 191 ± 53 | 210 [168, 233] | 192[156, 216] | 0.080 |
ECC duration (min) | 121 ± 39 | 110 [95,135] | 110 [98, 142] | 0.918 |
Intraoperative transfusion (%) | 133 (76) | 82 (74.5) | 51 (87.9) | 0.067 |
Post-operative data | ||||
VA-ECMO post-HTx (%) | 114 (66) | 68 (58.6) | 47 (79.7) | 0.009 |
Revision surgery (%) | 39 (22) | 20 (17.5) | 19 (33.3) | 0.033 |
SAP 2 score in ICU | 43 (±15) | 40 [30,50] | 50 [34,58] | 0.02 |
SOFA score in ICU | 6 (±3) | 6[4,8] | 6 [4,8] | 0.70 |
Post-HTx transfusion (%) | 60 (34) | 25 (21.7) | 35 (59.3) | < 0.001 |
Immunosuppressive therapy | ||||
Plasmapheresis (%) | 69 (39) | 40 (34.5) | 29 (49.2) | 0.087 |
Polyvalent Immunoglobulin(%) | 85 (48) | 54 (46.6) | 31 (53.4) | 0.486 |
Anti-thymocyte globulin (%) | 169 (95) | 111 (95) | 56 (94.9) | 1.000 |
Basiliximab (%) | 6 (5) | 5 (4.3) | 1 (1.7) | 0.665 |